Is CJC-1295 Ipamorelin FDA Approved? The 2026 Legal Status

Why Isn't CJC-1295 Ipamorelin FDA Approved?

No CJC-1295 ipamorelin FDA approved product exists: FDA has approved neither peptide, alone or as a pair. Under Section 503A of federal law, pharmacies have no lawful way to compound them either. FDA's advisers voted against listing both peptides in late 2024. When the advisers met again in July 2026, neither was on the agenda.

FDA approval needs clinical trials that show a drug is safe and works. Neither peptide made it through them. ConjuChem pulled CJC-1295 from clinical trials in 2006, after a participant in its Phase 2 study died (FDA review). A Phase 2 study is a mid-stage trial in patients. Ipamorelin reached that stage too, in adults recovering from bowel surgery. It did no better than placebo on the main measure (Beck et al.).

FDA has approved close relatives of both peptides. Tesamorelin (Egrifta SV) copies the same brain signal as CJC-1295. It is approved only to cut excess belly fat in adults with HIV and lipodystrophy. That condition shifts where the body stores fat. It is injected once a day (Egrifta SV label). Macimorelin (Macrilen) works on the same receptor as ipamorelin. It is approved only to help diagnose growth hormone deficiency in adults (FDA review). We compare tesamorelin and ipamorelin in a separate piece.

CJC-1295 is not approved abroad either. FDA found no approved product with any form of it in 12 countries, including Canada, Japan and the UK. None is authorised in the EU (FDA review).

The pairing itself rests on one idea. Each peptide pushes growth hormone (GH) release through a different receptor. Here is what each one does, and what has been tested in people.

CJC-1295: A Longer-Acting GHRH Copy

CJC-1295 copies growth hormone releasing hormone, or GHRH. GHRH is the brain signal that tells the pituitary to release GH. The natural hormone wears off fast, and that limits its use as a drug (Teichman et al.).

The useful trick is DAC, short for drug affinity complex. It is a chemical hook that binds the peptide to albumin, a protein in your blood. That link is thought to be what makes it last so long. In healthy adults, its half-life (how long it stays active in your body) was 5.8 to 8.1 days (Teichman et al.). FDA says studies suggest the DAC form acts like GHRH1-29 to trigger GH release. GHRH1-29 is a shorter piece of the natural hormone that still works fully. It acts on GHRH receptors on the pituitary cells that make GH. The version sold without DAC has no such hook. FDA found no study showing it is active at all (FDA review).

Ipamorelin: A Picky Ghrelin Receptor Agonist

It is a short peptide, five amino acids long, first made at Novo Nordisk. Ipamorelin is an agonist at the ghrelin receptor (GHS-R1a), which means it switches that receptor on. The ghrelin receptor is a second trigger for GH release. FDA says ipamorelin works mainly through nerve cells in the hypothalamus, the brain area that drives the pituitary (FDA review).

Its selling point is selectivity. In pigs, the older peptides GHRP-6 and GHRP-2 raised cortisol, a stress hormone. They also raised ACTH, the signal that releases it. Ipamorelin did not, even at more than 200 times its effective dose for GH. None of them changed prolactin, another pituitary hormone (Raun et al.). We set out the selectivity argument in our Ipamorelin guide.

What the Pairing Adds

Put them together and you press two separate buttons that both end in GH release. That is the whole case for the pair, and it rests on mechanism alone. All three published human studies of CJC-1295 that FDA found gave it alone, to healthy adults. None of them added ipamorelin.

FDA also found the two sold online as ready-made blends, labelled for research use only. The sellers did not say which form of CJC-1295 went in (FDA review). For how people use the pair, see our CJC-1295 ipamorelin stack guide. For the vial math on a blend, see our CJC-1295 ipamorelin dosage calculator.

One limit applies to both. They only work if your pituitary can still make GH. FDA notes that people with complete GH deficiency will not respond to them. Approved growth hormone (HGH) is different, because it replaces the hormone itself (FDA review).

The Human Evidence So Far

The human record is small, and none of it tests the pair.

Teichman and colleagues tested CJC-1295 in healthy adults aged 21 to 61. They ran two trials against placebo, lasting 28 and 49 days. One injection raised mean GH 2 to 10 fold, depending on dose, for 6 days or more. IGF-1, the growth factor GH drives, rose 1.5 to 3 fold for 9 to 11 days. After repeat doses, IGF-1 stayed above baseline for up to 28 days. No serious adverse reactions were reported. The peptide was relatively well tolerated, particularly at 30 or 60 mcg/kg (Teichman et al.).

A second study found that GH still came in pulses, its normal pattern. A week after one injection in healthy young men, the size and frequency of the pulses were unchanged. Trough GH, the level between pulses, was 7.5 times higher (Ionescu and Frohman).

FDA pooled the three published studies. Across them, 63 healthy adults received the peptide. Of those, 87% were men and 73% got a single injection. Injection site reactions were the most common side effect (FDA review).

For ipamorelin, FDA's review leans on that bowel surgery trial. It enrolled 117 adults, and 114 of them were dosed. Of those, 56 got ipamorelin and 58 got placebo (FDA review). They had it through a drip, twice a day, for up to 7 days. Ipamorelin was well tolerated. But it did no better than placebo on time to a first solid meal (Beck et al.).

That is close to the whole human file. The studies lasted days or weeks at most, and none tested the two peptides together. So the case for the pair still rests on the mechanism.

Is Compounded CJC-1295 Ipamorelin FDA Approved?

No compounded drug is FDA approved, whatever it contains. FDA does not review compounded products for safety, effectiveness or quality before they are sold (FDA slides). So the real question is whether a pharmacy may compound these peptides at all.

Section 503A sets the rules for pharmacy compounding. A pharmacy may use a bulk ingredient only if it passes one of three tests.

1. It has a USP or NF monograph, an official quality standard.
2. It is part of an FDA-approved drug.
3. It is on the 503A bulks list, a short list FDA writes into its rules.

Both peptides fail all three. FDA's reviews confirm that neither has a monograph and neither is part of an approved drug. The bulks list names six substances, and neither peptide is on it (eCFR).

FDA does give some leeway to ingredients it is still reviewing, which it calls category 1 (FDA policy). Neither peptide is in category 1 on FDA's current list (FDA list). And even a listed ingredient would not make the result FDA approved. The bulks list rule itself says that calling such a drug FDA approved misbrands it, which breaks federal labelling law.

Outsourcing facilities, which compound under Section 503B, have no route either. Neither peptide is on FDA's 503B bulks list (FDA 503B bulks list). FDA's list of ingredients nominated under 503B puts ipamorelin acetate in category 2. It does not name CJC-1295 at all (FDA 503B list).

The FDA Record, Date by Date

Two points in that record matter most. The committee only advises, and FDA is not legally bound to follow it (FDA). But here the committee and FDA's own reviews point the same way.

The Road to a Lawful Route

The bulks list is the route FDA's advisers were asked about. Adding a peptide to it takes rulemaking, a formal rule change (FDA slides). The advisers have already voted against both, and neither was part of the July review. Our report on the July 2026 FDA peptide vote covers the seven that were.

True FDA approval is a separate path. A company would have to test the drug in trials under an investigational new drug application, or IND, and then apply for approval. FDA calls that route the most efficient path to market.

The Side Effects FDA Has Flagged

FDA's reviews looked at each peptide separately, and neither assessed the pair. Both sit on its page of compounding ingredients that may carry significant safety risks (FDA safety page).

FDA says compounded CJC-1295 may pose a risk of immunogenicity for some routes. That means an immune reaction against the drug. FDA also flags impurities and trouble pinning down exactly what the ingredient is. It cites serious adverse events too. These include a raised heart rate and systemic vasodilatory reactions, where blood vessels widen across the body. FDA adds that clinical data are limited.

In one of the healthy adult trials, about 70% of people given the peptide had injection site reactions. Headache, nausea, diarrhoea, dizziness and low blood pressure also turned up across the studies (FDA review).

Animal work adds more. Daily injections caused bleeding, inflammation and tissue death at the injection site in rodents (rats) and dogs. The DAC form also showed signs of DNA damage, in rodent (mouse) pituitary cells and in live animals. With no long-term cancer studies, FDA says pituitary overgrowth or tumours cannot be ruled out.

Then there is the 2006 death. ConjuChem's Phase 2 study enrolled 192 people with HIV lipodystrophy. One participant reported chest discomfort two hours after an 11th weekly dose. The participant died about an hour later. The attending doctor's most likely explanation was heart artery disease that had caused no symptoms. FDA calls these reports anecdotal. The study's data were never published.

For ipamorelin, FDA flags the same immune risk. It adds that ipamorelin contains unnatural amino acids. Those make the peptide harder to characterise. In the bowel surgery trial, two patients given ipamorelin died. FDA says it is unclear whether the drug played a part. Low potassium, and high blood sugar at discharge, were also more common on ipamorelin than on placebo (FDA review).

FDA raised further concerns from animal and drug class data. As a ghrelin receptor agonist, ipamorelin may have properties that can feed addiction. It may also affect reproductive health. FDA also could not rule out the blood sugar problems seen with approved drugs that raise GH, such as diabetes. Our CJC-1295 side effects guide covers the single peptide in more depth.

Where This Leaves the Pairing in 2026

The legal answer is clear for now. Neither peptide is an FDA approved drug, and neither has a lawful route through Section 503A. FDA's advisers voted against both in 2024, and the July review went to seven other peptides.

The science is thinner than the enthusiasm. The mechanism has evidence behind it only for the DAC form of CJC-1295. FDA found no study showing the version without DAC works at all. The human data are small, short and single-peptide, and FDA's safety concerns stand on the record.

Seeing a clinic page that says the position has changed? Check it against the FDA's own record, starting with the documents listed below. If you want the dosing detail for research context, we cover it in our CJC-1295 dosing guide. Always work with a qualified clinician before making changes to your health protocol.

References

• Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91:799-805. PubMed 16352683.
• Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139:552-561. PubMed 9849822.
• Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91:4792-4797. PubMed 17018654.
• Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29:1527-1534. PubMed 25331030.
• FDA. FDA Evaluation of CJC-1295-Related Bulk Drug Substances. Briefing document, Pharmacy Compounding Advisory Committee, 4 December 2024. fda.gov.
• FDA. FDA Evaluation of Ipamorelin-Related Bulk Drug Substances. Briefing document, Pharmacy Compounding Advisory Committee, 29 October 2024. fda.gov.
• FDA. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, 29 October 2024. fda.gov.
• FDA. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, 4 December 2024. fda.gov.
• FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 22 April 2026. fda.gov.
• FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A. Updated 14 May 2026. fda.gov.
• FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503B. Updated 21 March 2025. fda.gov.
• FDA. 503B Bulk Drug Substances List. Updated 21 August 2023. fda.gov.
• FDA. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A. Guidance for industry, January 2025. fda.gov.
• 21 CFR 216.23. Bulk drug substances that can be used to compound drug products in accordance with section 503A. ecfr.gov.
• Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting. Vol. 91, No. 73, 16 April 2026. govinfo.gov.
• FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov.
• FDA. FDA presentations, Pharmacy Compounding Advisory Committee, 23 July 2026. fda.gov.
• EGRIFTA SV (tesamorelin for injection) prescribing information, revised February 2024. Drugs@FDA.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.